Toosendanin inhibits the malignant biological behaviors of esophageal squamous cell carcinoma KYSE150 cells by downregulating HIF1A expression via the AKT/mTOR pathway

CHU Yueming; ZHU Maofei; JIANG Hangyu; YUAN Qiang; LI Xing; LIU Kang; LI Lin

doi:10.3872/j.issn.1007-385x.2025.07.007

Chinese Journal of Cancer Biotherapy, Volume. 32, Issue 7, 723(2025)

Toosendanin inhibits the malignant biological behaviors of esophageal squamous cell carcinoma KYSE150 cells by downregulating HIF1A expression via the AKT/mTOR pathway

CHU Yueming^1,2, ZHU Maofei^1,2, JIANG Hangyu³, YUAN Qiang¹, LI Xing^1,2, LIU Kang⁴, and LI Lin^1,5

Author Affiliations

¹Department of Pharmacy, The Second Clinical Medical College of North Sichuan Medical College, Nanchong 637000, Sichuan, China

²School of Pharmacy, North Sichuan Medical College, Nanchong 637000, Sichuan, China

³Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China

⁴Institute of Tissue Engineering and Stem Cells, The Second Clinical Medical College of North Sichuan Medical College, Nanchong 637000, Sichuan, China

⁵Nanchong Key Laboratory of Individualized Drug Therapy, Nanchong 637000, Sichuan, China

show less

Abstract Get PDF(in Chinese)

Figures & Tables(0)

Tools

Get Citation

Copy Citation Text

CHU Yueming, ZHU Maofei, JIANG Hangyu, YUAN Qiang, LI Xing, LIU Kang, LI Lin. Toosendanin inhibits the malignant biological behaviors of esophageal squamous cell carcinoma KYSE150 cells by downregulating HIF1A expression via the AKT/mTOR pathway[J]. Chinese Journal of Cancer Biotherapy, 2025, 32(7): 723

Download Citation

EndNote(RIS)BibTex Plain Text

Set citation alerts for article

Save article for my favorites

Paper Information

Category:

Received: Oct. 8, 2024

Accepted: Aug. 26, 2025

Published Online: Aug. 26, 2025

The Author Email:

DOI:10.3872/j.issn.1007-385x.2025.07.007

Topics